29397 AGOURA RD., AGUORA HILLS, CA
Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
To Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
To Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
Material Contracts, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities
Oncotelic Therapeutics Enters Restricted Stock Agreement with Dr. Vuong Trieu
Oncotelic Therapeutics Enters Amendment to Contractor Agreement with Jefferso...
Oncotelic Therapeutics Completes Tranche 3 of Subscription Agreement
News, Material Contracts
Notice of Late Filing for Annual Report
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
Notice of Exempt Offering of Securities
S-1
Definitive Proxy Statement
PRER14A
PRE 14A
PRER14C
Preliminary Information Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload